Author: admin

Primary Sclerosing Cholangitis Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | GRI-0124, QBT-002, STP707, CS0159, CM 101, more

“Primary Sclerosing Cholangitis Pipeline”
As per DelveInsight’s assessment, globally, Primary Sclerosing Cholangitis pipeline constitutes 14+ key companies continuously working towards developing 14+ Primary Sclerosing Cholangitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

(Albany, USA) “Primary Sclerosing Cholangitis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Primary Sclerosing Cholangitis Market.

The Primary Sclerosing Cholangitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, FDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Request for Sample Report @ Primary Sclerosing Cholangitis Pipeline Insight

 

Some of the key takeaways from the Primary Sclerosing Cholangitis Pipeline Report:

  • Primary Sclerosing Cholangitis Companies across the globe are diligently working toward developing novel Primary Sclerosing Cholangitis treatment therapies with a considerable amount of success over the years. 
  • Primary Sclerosing Cholangitis companies working in the treatment market are Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others, are developing therapies for the Primary Sclerosing Cholangitis treatment 
  • Emerging Primary Sclerosing Cholangitis therapies in the different phases of clinical trials are- Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others are expected to have a significant impact on the Primary Sclerosing Cholangitis market in the coming years.   
  • In November 2023, Chemomab Therapeutics Ltd. (Nasdaq: CMMB), a clinical-stage biotech firm dedicated to pioneering treatments for fibro-inflammatory diseases with significant unmet needs, has revealed that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to CM-101 for treating primary sclerosing cholangitis (PSC) in adult patients. PSC is a fibrotic liver ailment associated with risks like liver transplant, cancer, and premature mortality.
  • In September 2023, Pliant Therapeutics, Inc. (Nasdaq: PLRX), has announced encouraging findings from the INTEGRIS-PSC Phase 2a clinical trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected moderate to severe liver fibrosis. The trial successfully achieved its primary and secondary objectives, indicating favorable tolerance of bexotegrast over a 12-week treatment period, with its plasma levels escalating proportionally to dosage. Furthermore, the trial explored efficacy through endpoints such as alterations in liver fibrosis markers (including Enhanced Liver Fibrosis (ELF) score and PRO-C3 levels), liver biochemistry, and magnetic resonance imaging (MRI) of the liver.
  • In March 2023, Pliant Therapeutics, Inc. revealed the initiation of enrollment in a Phase IIa trial of bexotegrast at a dosage of 320 mg administered once daily for a duration ranging from at least 24 weeks to up to 48 weeks. This trial focuses on patients diagnosed with primary sclerosing cholangitis (PSC) following a favorable safety review conducted by an independent Data Safety Monitoring Board (DSMB).

 

Primary Sclerosing Cholangitis Overview

Primary Sclerosing Cholangitis (PSC) is a chronic liver disease characterized by inflammation and scarring (fibrosis) of the bile ducts inside and outside the liver. This progressive condition obstructs the flow of bile, leading to liver damage and complications such as cirrhosis, liver failure, and an increased risk of bile duct cancer (cholangiocarcinoma). The exact cause of Primary Sclerosing Cholangitis is unknown, but it is believed to involve an abnormal immune system response, possibly triggered by genetic factors or environmental influences. Primary Sclerosing Cholangitis often occurs in association with other autoimmune conditions such as inflammatory bowel disease (IBD), particularly ulcerative colitis. Symptoms of Primary Sclerosing Cholangitis vary but can include fatigue, itching, jaundice (yellowing of the skin and eyes), abdominal pain, and weight loss. Diagnosis typically involves blood tests, imaging studies (such as MRI or ERCP), and liver biopsy to evaluate liver function and assess the extent of bile duct damage. While there is no cure for Primary Sclerosing Cholangitis, treatment aims to manage symptoms, slow disease progression, and prevent complications. This may involve medications to relieve symptoms and reduce inflammation, endoscopic procedures to widen narrowed bile ducts, liver transplantation in advanced cases, and ongoing monitoring to detect and manage complications early.

 

Get a Free Sample PDF Report to know more about Primary Sclerosing Cholangitis Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight

 

Emerging Primary Sclerosing Cholangitis Drugs Under Different Phases of Clinical Development Include:

  • Research programme: antifibrotic therapeutics Engitix
  • GRI-0124: GRI Bio
  • QBT-002: Qing Bile Therapeutics
  • STP707: Sirnaomics
  • CS0159: Cascade Pharmaceuticals
  • CM 101: Chemomab Therapeutics
  • Volixibat: Mirum Pharmaceuticals
  • PLN-74809 (bexotegrast): Pliant Therapeutics, Inc.
  • HTD1801: HighTide Biopharma
  • Norursodeoxycholic acid: Dr. Falk Pharma
  • Volixibat: Mirum Pharmaceuticals
  • Seladelpar: CymaBay Therapeutics
  • Elafibranor: Ipsen/Genfit
  • A3907: Albireo/IPSEN

 

Primary Sclerosing Cholangitis Route of Administration

Primary Sclerosing Cholangitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Primary Sclerosing Cholangitis Molecule Type

Primary Sclerosing Cholangitis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Primary Sclerosing Cholangitis Pipeline Therapeutics Assessment

  • Primary Sclerosing Cholangitis Assessment by Product Type
  • Primary Sclerosing Cholangitis By Stage and Product Type
  • Primary Sclerosing Cholangitis Assessment by Route of Administration
  • Primary Sclerosing Cholangitis By Stage and Route of Administration
  • Primary Sclerosing Cholangitis Assessment by Molecule Type
  • Primary Sclerosing Cholangitis by Stage and Molecule Type

 

DelveInsight’s Primary Sclerosing Cholangitis Report covers around 14+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Primary Sclerosing Cholangitis product details are provided in the report. Download the Primary Sclerosing Cholangitis pipeline report to learn more about the emerging Primary Sclerosing Cholangitis therapies – https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight

 

 

Some of the key companies in the Primary Sclerosing Cholangitis Therapeutics Market include:

Key companies developing therapies for Primary Sclerosing Cholangitis are – HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., Chemomab Therapeutics, CymaBay Therapeutics, Genfit, Albireo, IPSEN, and others.

 

Primary Sclerosing Cholangitis Pipeline Analysis:

The Primary Sclerosing Cholangitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Primary Sclerosing Cholangitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Primary Sclerosing Cholangitis Treatment.
  • Primary Sclerosing Cholangitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Primary Sclerosing Cholangitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Primary Sclerosing Cholangitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Primary Sclerosing Cholangitis drugs and therapies – https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight

 

Primary Sclerosing Cholangitis Pipeline Market Drivers

  • Increasing prevalence of diseases associated with PSC such as liver cancer and inflammatory bowel disease, a rising number of research studies on PSC are some of the important factors that are fueling the Primary Sclerosing Cholangitis Market.

 

Primary Sclerosing Cholangitis Pipeline Market Barriers

  • However, withdrawal of molecules from late clinical stages, lack of skilled professionals or trained expertise and other factors are creating obstacles in the Primary Sclerosing Cholangitis Market growth.

 

Scope of Primary Sclerosing Cholangitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Primary Sclerosing Cholangitis Companies: Engitix, GRI Bio, Qing Bile Therapeutics, Sirnaomics, Cascade Pharmaceuticals, Chemomab Therapeutics, Mirum Pharmaceuticals, Pliant Therapeutics, Inc., HighTide Biopharma, Dr. Falk Pharma, Mirum Pharmaceuticals, CymaBay Therapeutics, Ipsen, Genfit, Albireo, and others
  • Key Primary Sclerosing Cholangitis Therapies: Research programme-antifibrotic therapeutics, GRI-0124, QBT-002, STP707, CS0159, CM 101, Volixibat, PLN-74809 (bexotegrast), HTD1801, Norursodeoxycholic acid, Volixibat, Seladelpar, Elafibranor, A3907, and others
  • Primary Sclerosing Cholangitis Therapeutic Assessment: Primary Sclerosing Cholangitis current marketed and Primary Sclerosing Cholangitis emerging therapies
  • Primary Sclerosing Cholangitis Market Dynamics: Primary Sclerosing Cholangitis market drivers and Primary Sclerosing Cholangitis market barriers 

 

Request for Sample PDF Report for Primary Sclerosing Cholangitis Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/primary-sclerosing-cholangitis-pipeline-insight

 

Table of Contents

1. Primary Sclerosing Cholangitis Report Introduction

2. Primary Sclerosing Cholangitis Executive Summary

3. Primary Sclerosing Cholangitis Overview

4. Primary Sclerosing Cholangitis- Analytical Perspective In-depth Commercial Assessment

5. Primary Sclerosing Cholangitis Pipeline Therapeutics

6. Primary Sclerosing Cholangitis Late Stage Products (Phase II/III)

7. Primary Sclerosing Cholangitis Mid Stage Products (Phase II)

8. Primary Sclerosing Cholangitis Early Stage Products (Phase I)

9. Primary Sclerosing Cholangitis Preclinical Stage Products

10. Primary Sclerosing Cholangitis Therapeutics Assessment

11. Primary Sclerosing Cholangitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Primary Sclerosing Cholangitis Key Companies

14. Primary Sclerosing Cholangitis Key Products

15. Primary Sclerosing Cholangitis Unmet Needs

16 . Primary Sclerosing Cholangitis Market Drivers and Barriers

17. Primary Sclerosing Cholangitis Future Perspectives and Conclusion

18. Primary Sclerosing Cholangitis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Primary Sclerosing Cholangitis Pipeline Assessment 2024: FDA, EMA, PDMA Approvals, Clinical Trials, Therapies, MOA, ROA and Companies by DelveInsight | GRI-0124, QBT-002, STP707, CS0159, CM 101, more

In Play: Siyata Mobile Follows AT&T FirstNet® Deal With A $2.2 Million Order For Its SD7 PoC Handset ($SYTA)

Siyata Mobile (NASDAQ: SYTA) is proving that being different is good. Not only for itself but for its investors, evidenced by its stock price increasing over 23% to $3.23 at the time of this writing, well above the $2.61 level it closed last Friday. The potentially better news for investors, keeping in mind the adage “volume precedes price,” is that this impressive gain could be the precursor to even higher share prices. Monday’s volume was over 15X its average, and yesterday’s has already eclipsed the 7X mark heading into the final two hours of trading. 

The interest comes after two significant announcements related to its popular SD7 Push-to-Talk Over Cellular (PoC) handset. The first was on Monday, with SYTA announcing its revolutionary handset will be included in FirstNet®’s ‘Free Feature Phone for Life’ promotion, offered in collaboration with AT&T (NYSE: T). This promotion is a milestone deal that could provide a potentially significant and near-term steepening to SYTA’s revenue curve. That’s not an overly optimistic assessment, either. 

Not only does this deal highlight the increasing early adoption of its SD7 handsets, but it also comes with the marketing strength of an industry behemoth that can provide introductions to millions of customers and significantly expand its distribution footprint. That news was followed on Tuesday, with Siyata revealing that it has scored a deal worth $2.2 million for its flagship SD7 handsets and associated accessories. That’s significant, considering that this deal alone is worth more than the total revenues of $1.9 million posted in Q4 last year. Thus, the rally is deserved. 

Scoring Contract Wins That Deepen Market Penetration

And it should continue. Remember, inking deals with companies like AT&T doesn’t come easy. This one results from a rigorous review process that FirstNet Ready® devices undergo, meaning that the SD7 handset meets or exceeds stringent reliability, security, and performance standards. The SD7 checks those boxes, facilitating its addition to the FirstNet Ready® products arsenal available to PoC segment clients needing effective and durable devices during critical missions.  

More deals are likely to accrue. Keep in mind that Siyata is no newbie to the sector, with its product lineup having been instrumental in its pursuit to secure a global market leadership position in the fast-growing Push-to-Talk Over Cellular (PoC) sector. Thus, don’t be misled by the company’s current $2.26 million market cap. This company is performing in the major leagues of the industry and is disrupting traditional Land Mobile Radio (LMR) markets with innovative and, in many cases, unrivaled cellular technology. 

In fact, the SD7 handset is being described as the pinnacle of next-generation communication solutions. Why? Because unlike many competing products, Siyata designed its to seamlessly integrate with existing systems while offering unparalleled functionality. That difference and advantage allow the SD7 to uniquely bridge the gap between traditional two-way radios and modern cellular networks. 

Better still, from an investor’s perspective, its rugged design, military-standard durability, and reliable nationwide coverage have opened doors to major markets across various verticals, including first responders, security, education, commercial fleets, and construction teams. That’s certainly not an exhaustive list.

Market Expected To Breach $50 Billion By 2025

But don’t just consider the specific markets in play; consider the revenue potential. Siyata has its sights set on a combined addressable market opportunity north of $50 billion by 2025 in the North American markets alone. Most important to maximizing that potential is that this company has the right products to target the most potentially lucrative categories in the PoC industry. In addition to the SD7, the company offers in-vehicle mounted IoT cellular communications devices and cellular signal boosters for global first responders and enterprise customers.

Siyata’s extensive product portfolio is a crucial distinction, allowing it to penetrate markets quickly and take market share. They are already biting into share once held almost exclusively by the industry’s LMR behemoths like Motorola Solutions Inc. (NYSE: MSI), L3Harris Technologies Inc. (NYSE: LHX), and overseas brands such as JVC Kenwood Corp. (TSE: 6632) and Hytera Communications Corp (SZSE: 002583). The best part of the SYTA value proposition is that its steeping growth curve shows no signs of slowing.

On the contrary, growth is accelerating from the company aggressively capitalizing upon PoC market opportunities, including benefits earned by targeting complementary product categories whose synergies include using the same core channels and servicing the same customers. No other known competitor offers a similarly comprehensive portfolio of products, a distinction enabling Siyata to replace one-time ambition with real-time revenues from carriers that appreciate the breadth of its single-vendor asset portfolio. That difference is advantageous because it provides synergistic sales benefits and simplifies integration processes.

Targeting Multiple High-Dollar Market Opportunities

Still, while Siyata is targeting the rewards from providing field PoC applications, opportunities from In-Vehicle PoC solutions are also in the revenue-generating crosshairs. Siyata’s complementary and innovative VK7 is a first-in-class, in-car solution that pairs with its SD7. Like the company’s SD7, the VK7’s strength is its unique design, including connections to vehicle power, an integrated 10W speaker, a simple Slide-In connection, and internal active cooling. Additionally, the kit has a modularity that allows for the integration of multiple accessory solutions. 

Another product in the in-vehicle family is the UV350, an in-vehicle smartphone specifically designed to optimize mobile communications while driving. The UV350 is already considered a preferred IoT device for commercial vehicles because its 4G/LTE speed is always powered and supports FirstNet® certified apps, including fleet management, dispatch, GPS mapping, and other custom solutions. There’s more contributing to the value proposition.

The company also intends to drive higher revenues from its Channel Relationships, allowing it to market devices with global cellular carriers and distributors who sell to its enterprise customers. Leveraging these carrier sales channels and their broad customer base with its own core complementary product categories benefits brings a unique advantage in providing client carriers the ability to activate a SIM card and generate income otherwise not captured with customers using traditional LMR.

These advantages led to a deal with Bell Mobility Inc., a division of Bell Canada, that puts potential business from its more than 10 million subscribers into play. That’s not all. The company announced the addition of RadioTrader, the UK’s and Ireland’s premier two-way radio supplier, to distribute its mission-critical SD7 PoC device and VK7 vehicle kit accessory. That deal is expected to attract business from various industries that rely on RadioTrader and its over 20 years of industry experience for two-way radio solutions. Moreover, the addition of Siyata’s SD7 device and VK7 vehicle kit validates the quality of its products and, more importantly, could provide fuel to score considerably more near-term sales.

2023 Milestones To 2024 Catalysts

Based on recent deals announced, that’s indeed the case. Moreover, they show that Siyata is firing on all business cylinders and leveraging its status as a leading global vendor of next-generation Push-To-Talk over Cellular devices and cellular booster systems. That should keep the trend of excellent operating performance continuing.

Its deals this month alone support that bullish presumption. And remember, these agreements include promotional collaborations with one of the world’s largest carriers and distributors. In addition, Siyata appears to be gaining business traction where others aren’t, which puts hundreds of millions, if not billions, in its revenue crosshairs from laying the groundwork to keep the competitive landscape thin.

Thus, summing its parts and despite its May run, with best-in-class products and deals with top-tier clients, the disconnect between Siyata’s share price, assets, and potential remains wide. However, that’s not necessarily bad news for investors searching for value. In this case, that gap exposes an opportunity to position in a company that is changing the PoC landscape. And knowing that Wall Street windows of opportunity can close quickly, capitalizing sooner rather than later may be the best course of action.

 

Disclaimers: Hawk Point Media Group, Llc. is responsible for the production and distribution of this content.  Hawk Point Media Group, Llc. is not operated by a licensed broker, a dealer, or a registered investment adviser. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The information made available by  Hawk Point Media Group, Llc. is not intended to be, nor does it constitute, investment advice or recommendations. The contributors may buy and sell securities before and after any particular article, report and publication. In no event shall  Hawk Point Media Group, Llc. be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or made available by  Hawk Point Media Group, Llc., including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information in this video, article, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations.  Hawk Point Media Group, Llc. strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D from all featured companies. For some content,  Hawk Point Media Group, Llc., its authors, contributors, or its agents, may be compensated  for preparing research, video graphics, and editorial content. HPM, LLC has been compensated five-thousand-dollars via bank wire by IR Agency, Inc. to provide this research and/or editorial production coverage for Siyata Mobile, Inc. for a period starting on 05/15/24 and ending on 05/17/24. That compensation creates a conflict of interest because the content presented may only provide a favorable viewpoint of Siyata Mobile, Inc. The contributors do NOT buy and sell securities in the companies featured. HPM holds ZERO shares and has never owned stock in Siyata Mobile, Inc. Readers should be expect that those hiring HPM may sell some or all of the shares they own in Siyata Mobile, Inc., if any, before, during, or after this content is published. Readers, subscribers, and website viewers, are expected to read the full disclaimers and financial disclosures statement that are attached to this content. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled. 

Media Contact
Company Name: Hawk Point Media
Contact Person: Editorial Dept.
Email: info@hawkpointmedia.com
Country: United States
Website: https://hawkpointmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: In Play: Siyata Mobile Follows AT&T FirstNet® Deal With A $2.2 Million Order For Its SD7 PoC Handset ($SYTA)

Treatment AI’s (CSE: TRUE) New Developments Promise Significant Advancements in Medical Education

“HealthCare AI Stocks”
Health Care AI Stocks HEALWELL AI Inc (TSX: AIDX), HEALWELL AI Inc (OTCQX: HWAIF), Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc. (NASDAQ: GEHC), VERSES AI Inc (OTCMKTS: VRSSF), VERSES AI Inc (CBOE: VERS)

Treatment.com AI Inc. (CSE: TRUE, OTC: TREIF, Frankfurt: 939), a specializing in AI-driven healthcare solutions, has made significant strides with the announcement of two innovative products set to revolutionize medical education: AI Patient and AI Doctor in a Pocket. These new solutions are part of the company’s comprehensive Medical Education Suite (MES), which is designed to prepare the next generation of healthcare professionals with cutting-edge tools and resources.

Elevating Medical Education

Treatment’s MES is tailored to enhance clinical content education across the board, from basic patient interactions to advanced USMLE diagnostic evaluations and faculty benchmarking. By reducing faculty administration costs and time, the MES provides a broad spectrum of clinical experiences and offers students a digital self-test companion to deepen their diagnostic skills. The suite supports both students and faculty in preparing for the Objective Structured Clinical Examination (OSCE), a critical test used in 57 countries to assess the practical reasoning and diagnostic abilities of healthcare students.

A Growing Market

The U.S. alone has a significant market potential with 300 medical schools, 900 nursing schools, and a combined 372,000 medical and nursing students. Treatment.com is also expanding its discussions to include schools in the UK and Canada, indicating a broadening international reach.

Introducing AI Patient and AI Doctor in a Pocket

Set to launch in the second half of 2024, AI Patient and AI Doctor in a Pocket are monthly subscription-based SaaS solutions aimed at students, residents, and healthcare professionals.

– AI Patient utilizes AI and a robust library of test cases to help students prepare for multiple-choice questions (MCQs) and OSCE exams, ensuring they are well-prepared for critical evaluations.

– AI Doctor in a Pocket offers a mobile-friendly AI-powered clinical decision support tool, providing healthcare professionals and students with vital information and support during clinical practice.

Both solutions are underpinned by Treatment’s proprietary Global Library of Medicine (GLM), an extensive online medical library created with input from hundreds of credentialed clinicians worldwide, ensuring high-quality clinical information and support.

Leadership and Vision

Dr. Essam Hamza, CEO of Treatment.com AI, expressed his enthusiasm for the new solutions, highlighting their potential to support students throughout their education and into their professional practice. “Our goal is for students to be supported and excel during their medical education, and then utilize the same trusted platform as they move into practice,” he stated.

Strategic Growth and Contract Renewals

Adding to the momentum, Treatment.com recently announced a contract renewal with a leading U.S. medical school for its MES. This renewal underscores the growing pipeline and strong market demand for Treatment’s solutions. The MES aims to streamline the creation, administration, and grading of national exams such as the OSCE, reducing costs and administrative burden for medical schools.

New Executive Appointment

In a move to further bolster its leadership, Treatment.com appointed Richard Atkins as Chief Operating Officer. With over 30 years of experience in international sales, partnerships, executive management, and M&A, Atkins brings a wealth of knowledge to the team. His extensive background in healthcare technology, including work with major health-tech firms and innovative digital health solutions, positions him to accelerate Treatment’s expansion and commercialization efforts.

Dr. Hamza welcomed Atkins to the executive team, noting, “Richard understands the unique inflection point of our company and has committed to help with the execution of our aggressive commercialization phase.”

Overall, Treatment.com AI Inc (CSE: TRUE) continues to make significant advances in the field of medical education and healthcare technology. With the introduction of AI Patient and AI Doctor in a Pocket, the company is poised to support the next generation of healthcare professionals in unprecedented ways. As they expand their reach and enhance their offerings, investors and traders should keep a close watch on Treatment.com’s developments, as these innovations could lead to substantial growth and market impact.

The global artificial intelligence (AI) in healthcare market size was estimated at USD 15.1 billion in 2022 and it is expected to surpass around USD 187.95 billion by 2030, growing at a CAGR of 37% during the forecast period 2022 to 2030. North America AI in healthcare market was valued at USD 6.8 billion in 2022. This suggests that companies with a viable healthcare-related AI product could benefit from the growing use of AI in healthcare.

Other Health Care AI Stocks to keep an eye out include HEALWELL AI Inc (TSX: AIDX), HEALWELL AI Inc (OTCQX: HWAIF), Exscientia PLC (NASDAQ: EXAI), Certara Inc. (NASDAQ: CERT), Relay Therapeutics Inc. (NASDAQ: RLAY), BioXcel Therapeutics Inc. (NASDAQ: BTAI), Royalty Pharma PLC (NASDAQ: RPRX), Alphabet Inc. (NASDAQ: GOOGL), Amazon.com Inc. (NASDAQ: AMZN), International Business Machines Corp. (NYSE: IBM), GE HealthCare Technologies Inc. (NASDAQ: GEHC), VERSES AI Inc (OTCMKTS: VRSSF), VERSES AI Inc (CBOE: VERS)

Disclaimer: This news article is for information purposes only and is neither a solicitation or recommendation to buy nor an offer to sell securities. The Bull Report is not-a-registered-investment-advisor. The Bull Report is not a broker-dealer. Information, opinions, and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. The Bull Report accepts no liability for any losses arising from an investor’s reliance on the use of this material. Starting on Mar 15, 2024 The Bull Report has been compensated $47,000 per month for coverage of TRUE by Sunburst Capital Corp. The Bull Report and its affiliates or officers may purchase, hold, and sell shares of common stock of this stock, in the open market at any time without notice. The Bull Report will not update its purchases and sales of this stock in any future postings on The Bull Report’s websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words “may”, “would,” “will,” “expect,” “estimate,” “anticipate,” “believe,” “intend,” ” project,” and similar expressions and variations thereof are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *The Bull Report does not set price targets on securities. Never invest in a stock discussed on this website or in this email alert unless you can afford to lose your entire investment.

Sources: 

https://finance.yahoo.com/news/treatment-com-ai-welcomes-federal-120000957.html

https://www.cbc.ca/news/politics/federal-government-ai-investment-1.7166234

https://finance.yahoo.com/news/treatment-com-ai-funded-national-120000374.html

https://ca.finance.yahoo.com/news/healwell-ai-pentavere-achieves-validation-110000955.html

https://finance.yahoo.com/quote/TRUE.CN/

https://finance.yahoo.com/news/repeat-treatment-com-ai-announces-120000231.html

https://www.precedenceresearch.com/artificial-intelligence-in-healthcare-market#:~:text=The%20global%20artificial%20intelligence%20(AI,forecast%20period%202022%20to%202030.

Media Contact
Company Name: TheBullReport
Contact Person: Ward Abbott
Email: info@thebullreport.com
City: Dallas
State: Texas
Country: United States
Website: https://www.thebullreport.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Treatment AI\’s (CSE: TRUE) New Developments Promise Significant Advancements in Medical Education

Reputable Exterior Remodeling Contractors offering Quality and Reliable Services

Reputable Exterior Remodeling Contractors offering Quality and Reliable Services
The building exterior involves several things, all of which, when done well together, give a property a good look. Some exterior parts include the roof, sidings, doors and trim, which require the touch of a professional contractor to achieve the highest possible levels of quality and durability. Additionally, the quality products installed increase the value of the property.

Woodbridge, VA – Semper Fi Exteriors is a veteran-owned remodelling company that has helped homeowners transform their building exteriors into beautiful structures. The roofing company Woodbridge has several principles that guide the execution of its projects, including respect and integrity. The various principles have enabled them to provide a trustworthy and reliable service to all their clients.

In a previous website post, Semper Fi Exteriors highlighted its customer-centred service. The process first begins with a free in-home consultation to understand the client’s exact needs, and transparently, they guide the Roof Repair Woodbridge, client, on how best to execute the project and achieve the desired results. Also, the clients get guided accordingly during the project execution, which keeps them fully involved. 

As previously highlighted in their website post, Semper Fi Exteriors provides affordable services through their financing options. Woodbridge professionals’ roofing services have three financing options: n: paid in full in six months, no interest if paid in full in 12 months and 9.99% for 96 months. 

Semper Fi Exteriors has a good reputation for providing exceptional services to clients without bias. Their services’ customer-centred, thorough nature has enabled them to leave their clients with functional products that give them value for their money. 

About Us

Semper Fi Exteriors is a veteran operated and owned exterior building remodelling company with several years of experience. Call today for a quality service that improves property value. 

Media Contact
Company Name: Semper Fi Exteriors
Contact Person: Jennifer Ridgeway
Email: Send Email
Phone: (703) 775-2005
Address:13194 Centerpointe Way
City: Woodbridge
State: VA
Country: United States
Website: https://semperfiexteriors.net/

Hero Mold Company Explains the Dangers of Neglecting Mold Remediation

Hero Mold Company Explains the Dangers of Neglecting Mold Remediation
Hero Mold Company is a top-rated mold removal contractor. In a recent update, the contractor explained the dangers of neglecting mold remediation.

Winston-Salem, NC – In a website post, Hero Mold Company explained the dangers of neglecting mold remediation.

The experts asserted that mold can cause severe health issues for individuals living or working on the affected property. Mold spores may trigger allergies and respiratory issues such as sneezing, coughing, and difficulty breathing. In more severe cases, prolonged exposure to mold can lead to asthma, bronchitis, and other respiratory infections. Neglecting mold remediation Winston-Salem not only puts one’s health at risk but also that of others. 

The mold remediation company Winston-Salem said that ignoring mold remediation can lead to extensive property damage. Mold thrives on organic substances like wood, drywall, and carpets, causing them to deteriorate and rot over time. As mold spreads and grows, it can weaken the structure of a property, causing costly repairs. Furthermore, mold can also cause discoloration and staining of walls, ceilings, and other surfaces, reducing the aesthetic appeal of a property. 

Lastly, the mold company Winston-Salem noted that mold can also affect the air quality of a property. As mold spreads, it releases harmful mycotoxins into the air, leading to serious health problems when inhaled. Moreover, these mycotoxins can also cause a musty odor, making it unpleasant for occupants to live or work on the affected property. To ensure a conducive living or working environment, it is crucial to address mold remediation promptly.

About Hero Mold Company

Hero Mold Company is a premier mold removal contractor. The certified mold removal specialists take a comprehensive approach to mold removal, starting with a thorough inspection to identify the source of the problem. They then develop a customized plan to effectively remove the mold, ensuring that it is completely eradicated without causing any harm to the property or occupants. The professionals have the latest tools and strategies to effectively remove mold and avoid future growth.

Media Contact
Company Name: Hero Mold Company
Contact Person: Tabitha Westra
Email: Send Email
Phone: (336) 439-3594
Address:525 Vine St
City: Winston-Salem
State: NC
Country: United States
Website: https://heromoldcompany.com/winston-salem/

ReVisioned Exterior Painting Outlines Common Mistakes in Painting Over Old Exterior Surfaces

ReVisioned Exterior Painting Outlines Common Mistakes in Painting Over Old Exterior Surfaces
ReVisioned Exterior Painting is a leading exterior painting company. In a recent update, the company outlined common mistakes in painting over old exterior surfaces.

Northville, MI – In a website post, ReVisioned Exterior Painting outlined common mistakes in painting over old exterior surfaces.

The exterior painters Novi noted that one of the most common mistakes is not properly cleaning the surface before painting. This includes removing dirt, mildew, and any loose or flaking paint, which, when not removed, new paint can adhere unevenly or even peel off completely. To avoid this mistake, it is essential to thoroughly clean the exterior surface with a mild detergent and water, followed by a power wash if necessary. 

The best exterior painters Novi asserted that another mistake often made when painting over old exterior surfaces is not using a primer. Primer is essential for proper adhesion and to seal any imperfections on the surface. The new paint may not adhere evenly without a primer, resulting in an uneven finish. Choosing a primer specifically designed for the type of surface being painted is important. 

The Novi exterior painters added that many homeowners make the mistake of using the wrong type of paint for their exterior surfaces. It’s important to choose a paint that is appropriate for the specific surface being painted. Using an inappropriate type of paint can lead to problems such as cracking, peeling, and fading. Homeowners can ensure a professional and long-lasting finish by taking the time to research and choose the proper paint for the job.

About ReVisioned Exterior Painting

ReVisioned Exterior Painting is a top-rated exterior painting company. The proficient painters are dedicated to revamping the exterior appearance of properties with a methodical and thorough approach. They recognize that the exterior of a structure is the initial point of contact for individuals and are wholeheartedly dedicated to ensuring it presents a favorable and enduring impact. They prioritize the significance of creating a resilient and enduring outcome.

Media Contact
Company Name: ReVisioned Exterior Painting
Contact Person: Jason Weese
Email: Send Email
Phone: (248) 692-4244
Address:128 Walnut Street
City: Northville
State: Michigan
Country: United States
Website: https://revisionedhome.com/

Limestone Hills Orthodontics Explains How Invisalign Can Help Fix Common Dental Issues

Limestone Hills Orthodontics Explains How Invisalign Can Help Fix Common Dental Issues
Limestone Hills Orthodontics is a leading orthodontic facility in Austin TX, now commemorating 2 years in practice and launching a $1500 sale on braces and Invisalign. In a recent update, the facility explained how Invisalign can help fix common dental issues.

Austin, TX – In a website post, Limestone Hills Orthodontics explained how Invisalign can help fix common dental issues.

Dr. Viecilli, an orthodontist Austin TX relies on, mentioned that one of the ways Invisalign can help fix common dental issues is by correcting misalignment. Many people have crooked or misaligned teeth, which not only impacts the appearance of their smile but can also cause health issues like difficulty chewing and increased risk of tooth decay and periodontal disease. Invisalign aligners gently move the teeth into the desired position over time, resulting in a more aligned and healthier smile. Patients can remove the aligners to floss and brush keeping their teeth and gums clean and healthy. 

The professionals noted that another common dental issue that Invisalign Austin can fix is overcrowding. Overcrowding occurs when the mouth has insufficient space for all teeth to fit properly, or when there are discrepancies in tooth sizes and the bite. Invisalign aligners slowly shift the teeth into their right positions, creating more space and alleviating the strain on the jaw. Along with lowering the chance of gum disease, this can enhance oral health in general.

The experts said that Austin Invisalign can also help with bite issues, like overbites, underbites, or crossbites. A misaligned bite can result in jaw pain, difficulty chewing, and even speech issues. Invisalign aligners are customized to fit the patient’s mouth and gradually shift the teeth into the correct bite position. This improves the function of the mouth and the smile’s appearance. 

About Limestone Hills Orthodontics

Limestone Hills Orthodontics is a premier orthodontic facility. The company is committed to utilizing the latest technology and strategies to deliver personalized treatment plans for every patient. The doctors understand that every smile is unique and work closely with each individual to develop the most effective and efficient treatment plan for their orthodontic needs.

Media Contact
Company Name: Limestone Hills Orthodontics- Dr. Rodrigo F. Viecilli, DDS, PhD
Contact Person: Dr. Rodrigo F. Viecilli, DDS, PhD
Email: Send Email
Phone: (512) 720-6399
Address:7300 Ranch Rd 2222 Building 5, Suite 217
City: Austin
State: TX
Country: United States
Website: https://limestonehillsortho.com/

Highly Equipped Mold Removal Services That Improve the Life of Homeowners

Mold grows in moist areas and impacts the health of those in the house and the whole structure. Hero Mold Company began operations to provide complete service packages for mold removal and restoration for businesses and residential homes. Mold inspections, removal, black-green mold treatment, basement and crawlspace mold causes, attic mold causes, and your health.

Raleigh, NC – Hero Mold Company is a licensed and certified mold removal professional that provides the highest-quality mold removal service. Clients are provided with professional, experienced staff for mold inspection in Raleigh who ensure they get the best service. The company fully understands the do’s and don’ts of properly and efficiently caring for clients’ home and business needs. 

The quality service provided for water damage restoration Raleigh ensures that the defects that cause mold growth, like poor insulation and water leakages, are corrected, averting future mold occurrences. In addition, the company provides a wide range of services that ensure that any mold problems clients experience are professionally handled.

Hero Mold Company has unmatched availability, which enables clients to get services pronto. Clients can call or fill out the simple form on the company, and the Raleigh water damage restoration representative will contact the client as soon as possible. Also, clients get free estimates on inspections and treatment services for their mold removal projects with zero hassle and no obligations.

Hero Mold Company has the tools and expertise to deliver exceptional service that meets the needs of all its clients. The professionals use the tools at their disposal to finish the job on time and help their clients live healthy and comfortable lives. 

About Us

Hero Mold Company began operations to provide complete service packages for mold removal and restoration. For mold services, contact:

Media Contact
Company Name: Hero Mold Company of Raleigh
Contact Person: Autumn Prewett
Email: Send Email
Phone: (919) 263-0808
City: Raleigh
State: North Carolina
Country: United States
Website: https://heromoldcompany.com/raleigh-nc/

Water Heater Solutions Shares Tips for Maintaining Optimal Efficiency in Commercial Water Heating Systems

Water Heater Solutions Shares Tips for Maintaining Optimal Efficiency in Commercial Water Heating Systems
Water Heater Solutions is a top-rated plumbing company. In a recent update, the company shared tips for maintaining optimal efficiency in commercial water heating systems.

Fountain Valley, CA – In a website post, Water Heater Solutions shared tips for maintaining optimal efficiency in commercial water heating systems.

The plumber Fountain Valley mentioned that it is important to regularly inspect and maintain the water heating system. Over time, sediment and mineral deposits can accumulate in the tank, reducing its efficiency. This can also result in premature wear and tear, causing costly repairs or even replacement. Regularly flushing the tank and inspecting for leaks or damage can prevent these issues and ensure the system runs smoothly. 

The plumbing contractor Fountain Valley added that maintaining the proper temperature setting is crucial for optimal efficiency. Keeping commercial water heaters set between 120 and 140 degrees Fahrenheit is recommended. This ensures that water is hot enough for use and prevents overheating and excessive energy consumption. Regularly checking and adjusting the temperature can extend the system’s lifespan. 

Lastly, the professionals said that it is important to choose the right size and type of water heater for a commercial building. A water heater that is too small may struggle to keep up with the demand and constantly run, resulting in higher energy costs. On the other hand, a water heater that is too large may be unnecessarily expensive and waste energy. Consulting with a plumber in Fountain Valley to determine the suitable size and type of water heater for the building’s needs can ensure optimal efficiency and cost-effectiveness.

About Water Heater Solutions

Water Heater Solutions is a leading plumbing company. The team is dedicated to helping homeowners and businesses with all their water heater needs. The firm offers various services, including plumbing installation, repair, and maintenance. The skilled and certified technicians are equipped with the latest tools and strategies to ensure efficient and effective solutions for any plumbing issue.

Water Heater Solutions

16797 Pine Cir, Fountain Valley, CA 92708

(949) 877-7444

 

Media Contact
Company Name: Water Heater Solutions
Contact Person: Drew Miller
Email: Send Email
Phone: (949) 877-7444
City: Fountain Valley
State: California
Country: United States
Website: https://www.waterheatersolutions.com/

Redway Power Introduces Comprehensive LiFePO4 Voltage Chart (3.2V, 12V, 24V, 48V) Comparison Guide

Redway Power introduces a comprehensive LiFePO4 Voltage Chart Comparison Guide, offering insights into voltage dynamics across various configurations. From single cells to 48V setups, this resource empowers users to make informed decisions about energy solutions, ensuring safety and efficiency.

Redway Power, a renowned leader in the energy solutions industry, is thrilled to announce the launch of its comprehensive LiFePO4 Voltage Chart Comparison Guide. This in-depth resource offers consumers a detailed examination of LiFePO4 battery voltage across various configurations, empowering them to make informed decisions when selecting energy solutions.

LiFePO4 batteries have gained widespread recognition for their unparalleled safety, efficiency, and longevity. Redway Power’s latest guide features an extensive comparison chart, highlighting voltage levels for single cells (3.2V), 12V (four cells), 24V (eight cells), and 48V (sixteen cells) configurations. This invaluable resource caters to a broad spectrum of applications, ranging from small electronics to electric vehicles, while providing crucial insights into voltage dynamics necessary for monitoring battery performance and ensuring safe operation.

“At Redway Power, we are committed to providing consumers with the knowledge and tools they need to make informed decisions about their energy solutions,” said the spokesman of Redway Power. “Our LiFePO4 Voltage Chart Comparison Guide is designed to simplify the selection process by offering a comprehensive overview of voltage levels across various configurations, enabling users to choose the most suitable option for their specific requirements.”

The guide delves into key aspects of LiFePO4 battery voltage, including its significance, interpretation of the voltage chart, charging and discharging processes, performance implications, methods for checking battery capacity, and strategies for maximizing battery lifespan. By addressing these critical topics, Redway Power aims to equip consumers with the knowledge necessary to optimize their energy solutions effectively.

In addition to the comparison chart, Redway Power’s guide offers practical insights into the applications of LiFePO4 batteries. From RVs and boats to scooters and solar energy systems, these batteries serve as reliable power sources for a wide range of purposes. Understanding the nuances of LiFePO4 battery voltage is essential for maximizing efficiency and ensuring long-term reliability in these applications.

“As the demand for renewable energy solutions continues to grow, it’s crucial for consumers to have access to accurate and comprehensive information,” added the spokesman. “Our LiFePO4 Voltage Chart Comparison Guide not only simplifies the selection process but also empowers users to make informed decisions that align with their energy needs and sustainability goals.”

To access Redway Power’s LiFePO4 Voltage Chart Comparison Guide and learn more about the benefits of LiFePO4 batteries, visit Redway Power’s website.

About Redway Power:

Redway Power is a leading provider of innovative energy solutions, catering to the diverse needs of consumers worldwide. With a commitment to safety, efficiency, and sustainability, Redway Power offers a wide range of products and services designed to harness the power of renewable energy for a brighter future. From residential solar installations to commercial energy storage solutions, Redway Power is dedicated to empowering individuals and businesses to embrace renewable energy and reduce their carbon footprint.

Media Contact
Company Name: Redway Power, Inc.
Contact Person: Mr. Smith
Email: Send Email
Phone: +86 (755) 28010506
City: Shenzhen
State: Guangdong
Country: China
Website: https://www.redwaypower.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Redway Power Introduces Comprehensive LiFePO4 Voltage Chart (3.2V, 12V, 24V, 48V) Comparison Guide